Preferences help
enabled [disable] Abstract
Number of results
2016 | 6 | 1 | A29-36
Article title

Opposite changes of regulatory T cell blood content may differentially contribute to atherosclerosis or lymphoproliferative disorders

Title variants
Languages of publication
Background. Chronic autoimmune inflammation in arterial wall may lead to atherosclerosis progression. Objective. The aim of this study was to investigate the association between Treg, Th17 and B1a cell blood frequencies as well as IgM autoantibodies to oxLDL and the abundance of carotid atherosclerosis. Material and methods. 18 patients with increased IMT (intima-media thickness) and 65 patients with different severity of carotid atherosclerotic plaques were included. Treg, Th17 and B1a cell blood frequencies were assessed via direct immunofluorescence staining and flow cytometry, oxLDL as well as IgM autoantibodies to oxLDL were measured with commercial kits. Results. We observed higher values of Treg in patients without carotid atherosclerosis. Patients with intact carotid arteries as compared to patients with mild atherosclerotic plaques had decreased Th1 levels. OxLDL IgM levels were higher in patients with intact carotid arteries. Patients who received statin treatment had higher levels of Treg. Immunophenotyping of B cells revealed two cases of monoclonal B-cell lymphocytosis and 1 case of B-CLL (B-cell chronic lymphocytic leukemia) in elderly patients with intact carotid arteries. Conclusion. We hypothesize that certain parameters of cell immunity may hamper atherosclerosis while protecting from lymphoproliferative disorders.
Physical description
  • 1. Cheng X, Yu X, Ding YJ et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127: 89-97.
  • 2. Potekhina A, Pylaeva E, Provatorov S et al. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015; 238: 17-21.
  • 3. Kyaw T, Tipping P, Bobik A, Toh BH. Protective role of natural IgM-producing B1a cells in atherosclerosis. Trends Cardiovasc Med 2012; 22: 48-53.
  • 4. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, et al. ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-2906.
  • 5. Touboul PJ, Hennerici MG, Meairs S et al. Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011). An Update on Behalf of the Advisory Board of the 3rd, 4th and 5th Watching the Risk Symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 34: 290-296.
  • 6. Stein JH, Korcarz CE, Hurst RT et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force: Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111.
  • 7. Afanas’eva OI, Klesareva EA, Levashev PA et al. Autoantibodies against Lipoprotein(a) in patients with coronary heart disease. Kardiologiia 2014; 6: 4-8.
  • 8. Lindgren FT. Analysis of lipids and lipoproteins. American Oil Chemical Society, Amsterdam. 1975; 1: 204-224.
  • 9. Wieland E, Parthasarathy S, Steinberg D. Peroxidase-dependent metal-independent oxidation of low density lipoprotein in vitro: a model for in vivo oxidation? Proc Natl Acad Sci USA. 1993; 90: 5929-5933.
  • 10. Eichhorst B, Dreyling M, Robak T, et al. ESMO Guidelines Working Group: Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(suppl. 6): vi50-54.
  • 11. Kalpadakis C, Pangalis GA, Sachanas S et al. New insights into monoclonal B-cell lymphocytosis. Biomed Res Int 2014; 2014: 258917.
  • 12. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
  • 13. Khaidukov SV, Zurochka AV, Totolian A, Chereshnev VA. Major and minor lymphocyte populations of human peripherial blood lymphocytes and their reference values, as assayed by multi-colourcytometry. Med Immunol 2009; 11: 227-238.
  • 14. Wigren M, Björkbacka H, Andersson L et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol 2012; 32: 2000-2004.
  • 15. Hu Z, Li D, Hu Y, Yang K. Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 524-527.
  • 16. Liu ZD, Wang L, Lu FH et al. Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res 2012; 61: 1155-1165.
  • 17. Ziegelbauer K, Schaefer C, Steinmetz H et al. Clinical usefulness of carotid ultrasound to improve stroke risk assessment: ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). Eur J Prev Cardiol 2013; 20: 837-843.
  • 18. Meng X, Zhang K, Li J et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 2012; 18: 598-605.
  • 19. Rodríguez-Perea AL, Montoya CJ, Olek S et al. Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals. J Immunol Res 2015; 2015: 762506.
  • 20. Arnaud C, Veillard NR, Mach F. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 127-134.
  • 21. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831.
  • 22. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003; 108: 2107-2112.
  • 23. Seifert M, Sellmann L, Bloehdorn J et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209: 2183-2198.
  • 24. D’Arena G, Rossi G, Minervini MM et al. Circulating regulatory T cells in monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011; 24: 915-923.
  • 25. Dasgupta A, Mahapatra M, Saxena R. A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 28: 1-8.
  • 26. Tang D, Niu Q, Jiang N et al. Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: A one year follow-up. Pak J Med Sci 2014; 30: 1128-1133.
  • 27. Budczies J, von Winterfeld M, Klauschen F et al. Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. J Clin Pathol 2014; 67: 482-490.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.